Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Specialised Therapeutics Australia Pty, Ltd. (STA) announced today the execution of an exclusive agreement to register and commercialize fidaxomicin tablets in Australia and New Zealand for the treatment of Clostridium difficile Infection (CDI).
"CDI presents a serious bacterial health threat and current CDI treatment options are limited. Our license of fidaxomicin gives us a great opportunity to bring a highly differentiated and much-needed new therapy to patients in Australia and New Zealand," said Carlo Montagner, Chief Executive Officer of STA. "An application has already been filed with the Australian Therapeutic Goods Administration and pending approval, we are planning to launch fidaxomicin in mid 2013."
Under the agreement Optimer is entitled to receive commercial milestone payments upon the achievement of cumulative net sales targets. In addition, Optimer will also receive payments for the supply of fidaxomicin tablets to STA for a return equivalent to approximately 30% of expected fidaxomicin sales in Australia and New Zealand. STA is responsible for all costs associated with the registration and commercialization of fidaxomicin tablets in Australia and New Zealand.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.